

Supplementary Table 1.

Case-control and cohort studies addressing the relationship between HBV and CKD (outcome: frequency of end-stage renal disease or chronic kidney disease) (clinical characteristics)

*Numbers are reported as HBsAg positive/HBsAg negative patients, respectively

**Numbers are reported as untreated/uninfected patients, respectively

| | Follow-up, mo | Anti-HCV positive, n | HBsAg rate, n | Age, yrs |
|-----------------------------|-------------------|-------------------------|---------------------------|-----------------|
| Case-control studies | | | | |
| Chen Y, <i>et al.</i> | 6.5 | 0 | 20.0% (17,796/88,980) | NA |
| Su S, <i>et al.</i> | NA | 1.6% (169/10,463) | 3.6% (371/10,463) | 59.8+1/54+1* |
| Kim S, <i>et al.</i> | 0 | 0 | 20.0% (10,048/50,240) | 49.5+9/49.4+9 |
| Nguyen M, <i>et al.</i> | NA | 2.8% (1,221/43,482) | 26.5% (44,026/165,594) | NA |
| Cohort studies | | | | |
| Lo M, <i>et al.</i> | 1.99 (0.06-4.12) | NA | 15.4% (15/97) | 62.3+6.4 |
| Cheng A, <i>et al.</i> | 3.5 yrs | NA | 10.1% (286/2,838) | 59.7+12.9 |
| Chen Y, <i>et al.</i> | 6.5 yrs | 0 | 20.0% (17,758/88,790) | NA |
| Lee J, <i>et al.</i> | 2.2+1.6 | 6.5% (317/4,185) | 7.4% (309/4,185) | 61.9+14.8 |
| Kong X, <i>et al.</i> | 5 yrs | 0 | 8.1% (352/4,329) | 46.2+13.7 |
| Hwang J, <i>et al.</i> | 3.9+3.06 | 50.0% (9,787/19,574) | 5.4% (1,072/19,574) | 55.7+1 |
| Chen Y, <i>et al.</i> | 8.9+3.9/7.4+4.5** | 0 | 20.0% (2,916/14,580) | 48.1+1/47.7+1** |
| Si J, <i>et al.</i> | 9.1 yrs | NA | 3.1% (14,871/469,459) | 48.6/51.1* |
| Hong Y, <i>et al.</i> | 5.6 yrs | 0 | 3.9% (11,209/299,913) | 37.3+7.9 |
| Fang J, <i>et al.</i> | 25 (2-61) mo | 0 | 9.0% (16/177) | 32 (19-62) |
| Tartof S, <i>et al.</i> | 3.8+2.9 | 1.0% (1,534/152,708) | 0.3% (483/153,577) | 72 (64-80) |

Supplementary Table 2.

Case-control and cohort studies addressing the relationship between HBV and CKD
(outcome: frequency of end-stage renal disease or chronic kidney disease) (clinical characteristics)

| | Male, n | Diabetes mellitus, n | Hypertension, n | Cirrhosis, N |
|---------------------------------|----------------------------|---------------------------|----------------------------|-------------------------|
| Case-control studies | | | | |
| Chen Y, <i>et al.</i> | 58.5% (52,140/88,980) | 7.7% (6,841/88,980) | 12.9% (11,531/88,980) | 1.2% (1,104/88,980) |
| Su S, <i>et al.</i> | 37.2% (3,893/10,463) | 30.4% (3,182/10,463) | 55.4% (5,656/10,463) | NA |
| Kim S, <i>et al.</i> | 64.4% (32,355/50,240) | NA | NA | NA |
| Nguyen M, <i>et al.</i> | NA | 15.8% (6,873/43,482) | 36.1% (15,740/43,482) | NA |
| Cohort studies | | | | |
| Lo M, <i>et al.</i> | 63.4% (59/93) | 100.0% (97/97) | NA | NA |
| Cheng A, <i>et al</i> | 41.1% (1,169/2,838) | 100.0% (2,838/2,838) | NA | NA |
| Chen Y, <i>et al.</i> | 58.5% (51,990/88,790) | 7.9% (7,062/88,790) | 13.5% (12,035/88,790) | 1.2% (1,100/88,790) |
| Lee J, <i>et al.</i> | 58.4% (2,447/4,185) | 39.9% (1,673/4,185) | 61.0% (2,553/4,185) | 4.5% (177/4,185) |
| Kong X, <i>et al.</i> | 67.2% (2,907/4,329) | 10.5% (454/4,329) | 21.4% (927/4,329) | NA |
| Hwang J, <i>et al.</i> | 51.3% (10,044/19,574) | 100.0% (19,574/19,574) | 39.1% (7,659/19,574) | 5.7% (1,114/19,574) |
| Chen Y, <i>et al.</i> | 58.1% (8,475/14,580) | 26.0% (3,798/14,580) | 29.5% (4,304/14,580) | 4.1% (611/14,580) |
| Si J, <i>et al.</i> | 40.9% (192,445/469,459) | 5.4% (25,395/469,459) | 33.8% (158,908/469,459) | 1.2% (5,682/469,459) |
| Hong Y, <i>et al.</i> | 56.7% (170,050/299,913) | 2.4% (7,198/299,913) | 11.7% (35,089/299,913) | NA |
| Fang J, <i>et al.</i> | 17.5% (31/177) | NA | NA | NA |
| Tartof S, <i>et al.</i> | 45.9% (70,527/153,577) | 31.7% (48,735/153,577) | 61.1% (93,885/153,577) | 1.2% (1,948/153,577) |